SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

(2014) Bernard Zinman et al.   Cardiovascular Diabetology

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

(2014) David ZI Cherney et al.   Cardiovascular Diabetology

Treatment of Hypertension and Metabolic Syndrome: Lowering Blood Pressure Is Not Enough for Organ Protection, New Approach-Arterial Destiffening

(2014) Reuven Zimlichman   CURRENT HYPERTENSION REPORTS

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension

(2014) Ilkka Tikkanen et al.   DIABETES CARE

Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes

(2014) J. Dziuba et al.   DIABETES OBESITY & METABOLISM

Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

(2014) Marko Škrtić et al.   DIABETOLOGIA

Index of central obesity as a parameter to replace waist circumference for the definition of metabolic syndrome in predicting cardiovascular disease

(2014) Wenshu Luo et al.   Journal of Cardiovascular Medicine

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

(2014) Aurora Merovci et al.   JOURNAL OF CLINICAL INVESTIGATION

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

(2014) Ele Ferrannini et al.   JOURNAL OF CLINICAL INVESTIGATION

Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

(2014) Alan Sinclair et al.   BMC Endocrine Disorders

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

(2014) Martin Ridderstråle et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

(2014) Anthony H Barnett et al.   Lancet Diabetes & Endocrinology

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial

(2013) Bruce Neal et al.   AMERICAN HEART JOURNAL

Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations

(2013) Wendy L. Bennett et al.   ANNALS OF INTERNAL MEDICINE

Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

(2013) Despoina Vasilakou et al.   ANNALS OF INTERNAL MEDICINE

Hyperglycemia Promotes Myelopoiesis and Impairs the Resolution of Atherosclerosis

(2013) Prabhakara R. Nagareddy et al.   Cell Metabolism

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

(2013) David Z.I. Cherney et al.   CIRCULATION

The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988-2010

(2013) S. Stark Casagrande et al.   DIABETES CARE

Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials

(2013) M. Monami et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

(2013) H. J. Lambers Heerspink et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

(2013) J. Bolinder et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

(2013) J.-F. Yale et al.   DIABETES OBESITY & METABOLISM

Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial

(2013) et al.   EUROPEAN HEART JOURNAL

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

(2013)   EUROPEAN HEART JOURNAL

Uric acid and risk of heart failure: a systematic review and meta-analysis

(2013) He Huang et al.   EUROPEAN JOURNAL OF HEART FAILURE

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

(2013) Atsuo Tahara et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Incorporating Lag Time to Benefit Into Prevention Decisions for Older Adults

(2013) Sei J. Lee et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Sodium–glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?

(2013) Richard E. Gilbert   KIDNEY INTERNATIONAL

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

(2013) Donald E. Kohan et al.   KIDNEY INTERNATIONAL

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

(2013) William T Cefalu et al.   LANCET

The Cardiovascular Safety of Diabetes Drugs — Insights from the Rosiglitazone Experience

(2013) William R. Hiatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

(2013) William B. White et al.   NEW ENGLAND JOURNAL OF MEDICINE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?

(2013) Usha Panchapakesan et al.   PLoS One

Serum Uric Acid Is Not an Independent Risk Factor for Premature Coronary Artery Disease

(2013) Sara Zand et al.   CardioRenal Medicine

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus

(2013) Tim Heise et al.   Diabetes Therapy

Adiposopathy, Diabetes Mellitus, and Primary Prevention of Atherosclerotic Coronary Artery Disease: Treating “Sick Fat” Through Improving Fat Function with Antidiabetes Therapies

(2012) Harold E. Bays   AMERICAN JOURNAL OF CARDIOLOGY

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

(2012) J. Rosenstock et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

(2012) Jan Bolinder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Association of uric acid with mortality in patients with stable coronary artery disease

(2012) Gjin Ndrepepa et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Adipose tissue heterogeneity: Implication of depot differences in adipose tissue for obesity complications

(2012) Mi-Jeong Lee et al.   MOLECULAR ASPECTS OF MEDICINE

Sodium-Glucose Cotransporter Inhibition Prevents Oxidative Stress in the Kidney of Diabetic Rats

(2012) Horacio Osorio et al.   Oxidative Medicine and Cellular Longevity

Postprandial Hyperglycemia and Glycemic Variability: Should we care?

(2011) E. Standl et al.   DIABETES CARE

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

(2011) S. Sha et al.   DIABETES OBESITY & METABOLISM

Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1

(2011) Gian Paolo Fadini et al.   VASCULAR PHARMACOLOGY

Visceral Adiposity Index: A reliable indicator of visceral fat function associated with cardiometabolic risk

(2010) M. C. Amato et al.   DIABETES CARE

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET

Glucose Control by the Kidney: An Emerging Target in Diabetes

(2009) Olivera Marsenic   AMERICAN JOURNAL OF KIDNEY DISEASES

Uric Acid and Long-term Outcomes in CKD

(2009) Magdalena Madero et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

(2009) B Komoroski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Solute carrier family 2, member 9 and uric acid homeostasis

(2009) Chris Cheeseman   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans

(2009) M. Obermeier et al.   DRUG METABOLISM AND DISPOSITION

The Growing Burden of Diabetes Mellitus in the US Elderly Population

(2008) Frank A. Sloan   ARCHIVES OF INTERNAL MEDICINE

Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association

(2008) J. S. Skyler et al.   DIABETES CARE